Loading…
← CockpitCompetitor Analysis › 1858.HK Beijing Chunlizhengda Medical Instruments Co., Ltd. Class HOpen in the cockpit ↗

Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H1858.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Medical Specialties
Momentum neutral 42
Mkt cap
$631M
US dollars, full cap
Free float
95%
of shares outstanding
$/day
$380,556
20-day average traded
Fwd P/E
8.5×
forward earnings
ROIC−WACC
+18.0 pp
WACC 8.5%
Hurdle
-11 pp
Req g minus delivered
Next earnings
131 days
29 Mar 2027
Close · HKDHK$7.21
1D-0.3%
1W-3.0%
1M+1.2%
3M-16.9%
6M-28.2%
YTD-51.5%
1Y-62.2%
ATR %3.4%
52w lowhigh64.5% off high

What Beijing Chunlizhengda Medical Instruments does

Employees: 1,078

Beijing Chunlizhengda Medical Instruments at a glance

Size Beijing Chunlizhengda Medical Instruments (1858.HK) is a Hong Kong Health Care company (Medical Specialties) with a market value of $631M, the 689th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$7.21 on 18 Nov 2026.

Performance Over six months the shares fell 28.2%, against -6.6% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 4th lowest of 19 in its peer set.

Growth Revenue fell 9.0% over the last twelve months (peer median +17.8%); the operating margin is 30.7% (peer median 9.5%).

Valuation It trades at 8.5× forward earnings against a peer median of 27.9× (cheapest of 15).

Price implies For today's price to make sense, revenue must grow about -9% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is -11 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 18.0 points above its cost of capital (8.5% WACC).

Next results Next results expected around 29 Mar 2027 (exchange calendar; dates can move).

Relative performance

70809010021 May 202621 Aug 202618 Nov 2026Peer median 941858.HK 72
Six months, rebased to 100: Beijing Chunlizhengda Medical Instruments against the median of its 20 peers (local-currency closes).

Beijing Chunlizhengda Medical Instruments financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$1.04BHK$1.13BHK$867MHK$1.32BHK$1.39B
Revenue growth—+30%-34%-5%—
Gross profitHK$679MHK$712MHK$551MHK$931MHK$1.03B
EBITDAn/aHK$334MHK$136MHK$323MHK$358M
Net incomeHK$305MHK$296MHK$136MHK$307MHK$358M
Free cash flowHK$360MHK$392M-HK$33.0MHK$553MHK$50.4M
Capital expenditureHK$48.5MHK$64.1MHK$53.3MHK$36.7MHK$29.0M
Total debtHK$2.80MHK$4.20MHK$978,049HK$14.1MHK$20.5M

Quarterly statements and history in the cockpit →

Beijing Chunlizhengda Medical Instruments competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%-20%0%+20%47281789XVIVOQDELSNT300326MEDISGHTTCMD300314OBIO002876DCTH4910003009521858.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Beijing Chunlizhengda Medical Instruments is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%0×200×1789XVIVOQDELSNT300326NANMEDITCMD688581002876DCTH3009521858.HKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Beijing Chunlizhengda Medical Instruments is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%47281789XVIVOSNT300326NANTCMD688581DCTH1858.HKGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Beijing Chunlizhengda Medical Instruments is the large dot.

Beijing Chunlizhengda Medical Instruments competitors and peer comparison

How Beijing Chunlizhengda Medical Instruments compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Beijing Chunlizhengda Medical Instruments against its 20 peers (data as of 18 Nov 2026)
Measure1858.HKPeer medianRank in peer set
1-month return+1.2%-1.9%9th highest of 19
6-month return-28.2%-6.6%4th lowest of 19
Distance from 52-week high-64.5%-23.9%2nd lowest of 20
Revenue growth (TTM)-9.0%+17.8%3rd lowest of 20
Operating margin30.7%9.5%3rd highest of 20
Forward P/E8.5×27.9×cheapest of 15
Growth the price implies (Req g, 7 yrs)-9.5%7.5%2nd least demanding of 13
Growth delivered (Del g)+1.5%+14.3%2nd lowest of 13
Hurdle (Req g minus delivered)-11.0 pp-9.8 pp7th least demanding of 13
ROIC minus cost of capital+18.0 pp+2.0 pp4th highest of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Beijing Chunlizhengda Medical Instruments 1858.HKHong Kong$631M-28%-9%31%8.5×-9.5%+1.5%
SunMax Biotechnology 4728.TWOTaiwan$630M0%+19%51%n/a-2.6%+18.8%
AK Medical 1789.HKHong Kong$642M-23%+16%26%10.5×-11.5%+6.7%
Xvivo Perfusion XVIVO.STSweden$611M-32%+18%12%53.1×35.9%+35.2%
QuidelOrtho QDELUnited States$657M-20%-5%-2%10.7×n/an/a
Synektik SNT.WAPoland$662M+10%+32%24%13.8×0.2%+47.5%
Shanghai Kinetic Medical 300326.SZChina$662M-10%-28%17%26.0×6.6%-1.9%
Nanosonics NAN.AXAustralia$599M-4%+3%7%98.6×35.3%+6.7%
Medistim MEDI.OLNorway$599M+32%+19%29%31.8×-1.2%+14.5%
Sight Sciences SGHTUnited States$599M+122%+16%-30%n/an/an/a
Sahajanand Medical Technologies SMT.NSIndia$595Mn/an/an/an/an/an/a
vVARDIS VVVVUnited States$594Mn/a+148%-72%n/an/an/a
Tactile Systems Technology TCMDUnited States$592M+6%+14%9%21.1×8.4%+12.0%
Hangzhou AGS MedTech 688581.SSChina$590M-22%-18%33%18.9×0.4%+27.8%
Ningbo David Medical Device 300314.SZChina$589M+25%+19%11%12.0×n/an/a
Orchestra BioMed OBIOUnited States$587M+87%+1,007%-195%n/an/an/a
Shenzhen Sunnypol Optoelectornics 002876.SZChina$680M-9%+29%5%39.0×10.1%+14.2%
Delcath Systems DCTHUnited States$685M+75%+38%5%358.9×33.4%+120.2%
Livsmed 491000.KSSouth Korea$687M-47%+89%-77%n/an/an/a
Jiangsu Hanvo Safety Product 300952.SZChina$575M-38%+6%8%39.7×n/an/a
Shenzhen Lifotronic Technology 688389.SSChina$692M-14%+14%13%29.9×11.6%+13.3%

Questions

Which companies are Beijing Chunlizhengda Medical Instruments's closest peers?
The cockpit's peer set: SunMax Biotechnology (4728.TWO), AK Medical (1789.HK), Xvivo Perfusion (XVIVO.ST), QuidelOrtho (QDEL), Synektik (SNT.WA), Shanghai Kinetic Medical (300326.SZ), Nanosonics (NAN.AX), Medistim (MEDI.OL).
Is Beijing Chunlizhengda Medical Instruments expensive compared with its peers?
On forward p/e it trades at 8.5× against a peer median of 27.9×, cheapest of 15 in its peer set. For today's price to make sense, revenue must grow about -9% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is -11 pp: the price already allows for a slowdown.
How has Beijing Chunlizhengda Medical Instruments stock performed?
Over six months to 18 Nov 2026 the shares returned -28.2% against -6.6% for the median peer; over one year -62.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.